Cargando…

Performances of Functional and Anatomic Imaging Modalities in Succinate Dehydrogenase A-Related Metastatic Pheochromocytoma and Paraganglioma

SIMPLE SUMMARY: Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine cancers which carry the risk of metastatic disease. Pathogenic variants in the succinate dehydrogenase subunit A gene (SDHA) have been shown to cause metastatic disease, occurring in various regions of the body. Imagin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Mayank, Jha, Abhishek, Ling, Alexander, Chen, Clara C., Millo, Corina, Kuo, Mickey J. M., Nazari, Matthew A., Talvacchio, Sara, Charles, Kailah, Miettinen, Markku, Del Rivero, Jaydira, Chen, Alice P., Nilubol, Naris, Lin, Frank I., Civelek, Ali Cahid, Taïeb, David, Carrasquillo, Jorge A., Pacak, Karel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406057/ https://www.ncbi.nlm.nih.gov/pubmed/36010880 http://dx.doi.org/10.3390/cancers14163886

Ejemplares similares

RF21 | PSUN08 Morphologic or Molecular Imaging - Diagnostic Capabilities in von Hippel-Lindau related pheochromocytoma
por: Patel, Mayank, et al.
Publicado: (2022)

Postoperative Management in Patients with Pheochromocytoma and Paraganglioma
por: Mamilla, Divya, et al.
Publicado: (2019)

Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma
por: Ilanchezhian, Maran, et al.
Publicado: (2020)

PSUN27 Largest Cohort of Cervical Spine Metastases of Pheochromocytoma/Paraganglioma in the Setting of SDHB Mutation
por: Pacak, Karel, et al.
Publicado: (2022)

SAT305 Clinical Characteristics And Outcomes Of Patient With Metastatic Pheochromocytoma/Paraganglioma (PPGL) And Extreme Elevated Biochemistry
por: Prodanov, Tamara, et al.
Publicado: (2023)

Pheochromocytoma (PHEO) and Paraganglioma (PGL)
por: Pacak, Karel, et al.
Publicado: (2019)

PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma
por: Hadrava Vanova, Katerina, et al.
Publicado: (2022)

Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma
por: Jha, Abhishek, et al.
Publicado: (2019)

Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches
por: Kuo, Mickey J. M., et al.
Publicado: (2022)

Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World
por: Patel, Mayank, et al.
Publicado: (2021)

Personalized Management of Pheochromocytoma and Paraganglioma
por: Nölting, Svenja, et al.
Publicado: (2021)

New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications
por: Jhawar, Sakshi, et al.
Publicado: (2022)

MON-214 Biochemical Abnormalities in Endocrine Function Associated with Lutetium 177-DOTATATE Therapy in Metastatic Pheochromocytoma and Paraganglioma
por: Gubbi, Sriram, et al.
Publicado: (2020)

Novel Germline SUCLG2 Mutations in Patients With Pheochromocytoma and Paraganglioma
por: Vanova, Katerina Hadrava, et al.
Publicado: (2021)

Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity
por: Vit, Ondrej, et al.
Publicado: (2021)

Metabolome-guided genomics to identify mutations in isocitrate dehydrogenase, fumarate hydratase and succinate dehydrogenase genes in pheochromocytoma and paraganglioma
por: Richter, Susan, et al.
Publicado: (2018)

New insights on the pathogenesis of paraganglioma and pheochromocytoma
por: Kantorovich, Vitaly, et al.
Publicado: (2018)

SAT-310 (18)F-FDOPA PET/CT Accurately Identifies Pheochromocytoma in 70-Year-Old Male with MEN1
por: Tepede, Aisha, et al.
Publicado: (2019)

(18)F-FDOPA PET/CT accurately identifies MEN1-associated pheochromocytoma
por: Tepede, Aisha A, et al.
Publicado: (2020)

Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging
por: Blanchet, Elise M., et al.
Publicado: (2012)

SAT329 Case Series Of Patients With FGFR-1 Related Pheochromocytoma With A Focus On Biochemical And Imaging Signatures
por: Jhawar, Sakshi, et al.
Publicado: (2023)

Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [(177)Lu]Lu-DOTA-TATE therapy
por: Gubbi, Sriram, et al.
Publicado: (2023)

Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies
por: Pang, Ying, et al.
Publicado: (2019)

A novel mutation in the succinate dehydrogenase subunit D gene in siblings with the hereditary paraganglioma–pheochromocytoma syndrome
por: Prasad, Chaithra, et al.
Publicado: (2014)

A New Specific Succinate-Glutamate Metabolomic Hallmark in Sdhx-Related Paragangliomas
por: Imperiale, Alessio, et al.
Publicado: (2013)

RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective
por: Crona, Joakim, et al.
Publicado: (2018)

The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study
por: Schovanek, Jan, et al.
Publicado: (2014)

MON-199 Targeting Pheochromocytoma/Paraganglioma with Polyamine Inhibitors
por: Ghayee, Hans Kumar, et al.
Publicado: (2020)

Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma
por: Zhang, Liang, et al.
Publicado: (2023)

Succinate Mediates Tumorigenic Effects via Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas
por: Matlac, Dieter M., et al.
Publicado: (2021)

Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma
por: Gubbi, Sriram, et al.
Publicado: (2021)

The SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency
por: Bayley, Jean-Pierre, et al.
Publicado: (2005)

Pheochromocytomas and secreting paragangliomas
por: Plouin, Pierre-François, et al.
Publicado: (2006)

Succinate dehydrogenase‐deficient malignant paraganglioma complicated by succinate dehydrogenase‐deficient renal cell carcinoma
por: Yamaguchi, Yoshitomo, et al.
Publicado: (2022)

External Beam Radiation Therapy in Treatment of Malignant Pheochromocytoma and Paraganglioma
por: Vogel, Jennifer, et al.
Publicado: (2014)

Reactive Oxygen Species: A Promising Therapeutic Target for SDHx-Mutated Pheochromocytoma and Paraganglioma
por: Hadrava Vanova, Katerina, et al.
Publicado: (2021)

SAT-502 Clinical Hypothyroidism Associated with Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma: A Novel Adverse Effect of Peptide Receptor Radionuclide Therapy
por: Gubbi, Sriram, et al.
Publicado: (2020)

Succinate Dehydrogenase Complex Iron Sulfur Subunit B (SDHB) Immunohistochemistry in Pheochromocytoma, Head and Neck Paraganglioma, Thoraco-Abdomino-Pelvic Paragangliomas: Is It a Good Idea to Use in Routine Work?
por: Gul, Aylin Ege, et al.
Publicado: (2021)

Pheochromocytoma and paraganglioma: imaging characteristics
por: Baez, Juan C., et al.
Publicado: (2012)

Glycemic Disturbances in Pheochromocytoma and Paraganglioma
por: Ronen, Joshua A, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l2h6v0jqm10rgh15ko0ai9va9e